Here is the design of a clinical trial:

Official Title: Aerobic Exercise and Cognitive Functioning in Women With Breast Cancer: the ACTIVATE Trial

Included conditions:
- Breast Neoplasms

Study Armgroups:
- {'label': 'Aerobic Exercise', 'type': 'EXPERIMENTAL', 'description': 'Participants will complete three supervised aerobic exercise sessions each week using the treadmill, stationary bicycle or elliptical training for the duration of their chemotherapy (12-18 weeks). Aerobic exercise will be performed for 20-40 minutes at 50-75% of heart rate reserve. Participants will wear heart rate monitors during all supervised sessions (Polar Electro Inc., Lake Success, NY) and will be provided with target heart rates that will be individualized using their baseline (i.e., week 0) assessment data. Home-based exercise will be introduced in week 3. For the home-based sessions, participants will be asked to complete at least 1 session per week of 30 minutes of aerobic exercise (an activity of their choosing; e.g., walking).', 'interventionNames': ['Behavioral: Aerobic Exercise']}
- {'label': 'Usual Care (Wait-list Control)', 'type': 'OTHER', 'description': 'Participants randomly assigned to UC group will be advised to continue with their regular activities of daily living. Following their chemotherapy, the UC group will receive the exercise intervention (lasting 12 weeks).', 'interventionNames': ['Behavioral: Usual Care (Wait-list Control)']}

Interventions:
- {'type': 'BEHAVIORAL', 'name': 'Aerobic Exercise', 'description': 'Three weekly moderate-vigorous intensity supervised aerobic exercise training for the duration of adjuvant chemotherapy. Home-based exercise will also be introduced in week 3 of the intervention.', 'armGroupLabels': ['Aerobic Exercise']}
- {'type': 'BEHAVIORAL', 'name': 'Usual Care (Wait-list Control)', 'description': 'Three weekly moderate-vigorous intensity supervised aerobic exercise training starting upon adjuvant chemotherapy completion. Home-based exercise will also be introduced in week 3 of the intervention.', 'armGroupLabels': ['Usual Care (Wait-list Control)']}

Primary Outcomes:
- {'measure': 'Change with treatment and maintenance post-treatment in objective neuropsychology test battery composite score', 'description': 'A neuropsychological test battery. The tests are as follows: WAIS-IV (Digit-Symbol Coding, Letter-Number-Sequencing), Auditory Consonant Trigrams Test, Brief Visuospatial Memory Test Revised, Controlled Oral Word Association Test, Hopkins Verbal Learning Test-Revised, and Trail Making Test A\\&B. Alternate forms will be used, with the exception of the WAIS-IV tests, the Controlled Oral Word Association Test, and Trail Making A\\&B. These tests are combined to form a composite score called the COGSUM.', 'timeFrame': 'Pre-chemotherapy (baseline, week 0), end of chemotherapy (12-18 weeks post-baseline), follow-up/post-usual care group receiving intervention (24-34 weeks post-baseline), 1-year follow-up (52 weeks post-baseline)'}

Please estimate the sample size based on the assumption: 
80% power, two-sided 5% level of significance, correlation with baseline measure of 0.8, and a potential dropout rate of 10%.
Sample size
          A power calculation was performed to detect changes in cognitive functioning (as measured by a composite cognitive summary score (COGSUM; developed by Collins et al. [52â55]). Using a minimum clinically important difference of 0.4 standard deviation units between EX versus UC at post-chemotherapy (i.e., post-intervention/post-wait period; primary endpoint), a total sample size of 74 women is needed to achieve 80% power using an analysis of covariance (ANCOVA) at a two-sided 5% level of significance. The correlation with the baseline measure was assumed to be 0.8. To account for a potential dropout rate of 10%, a sample of 84 participants (42 per condition) will be recruited.